1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Industry Analysis, May 2019

Healthcare Industry Analysis, May 2019

Customer Support

Talk to Veronica

+1 718 514 2762

Publishers

  • All
    • La Merie Publishing

data types

  • All
    • Industry Data
1-17 of 17 reports

Competitor Analysis: CDK9 and Mcl-1 Inhibitors

Competitor Analysis: CDK9 and Mcl-1 Inhibitors

  • $ 228
  • Industry report
  • March 2018

Competitor Analysis: CDK9 and Mcl-1 InhibitorsThis Competitive Intelligence report about CDK9 and Mcl1 Inhibitorsprovides a competitor evaluation in the field of inhibitors of CDK9 and Mcl-1 as of March ...

  • Industries : Cancer
mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals

  • $ 2565
  • Industry report
  • June 2017

mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals For a long time, messenger RNA (mRNA) was thought to be a poor choice for a therapeutic agent ...

  • Industries : Therapy, Pharmaceutical, Medical Biotechnology
  • Countries : Australia
The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities

  • $ 2451
  • Industry report
  • January 2017

The Oncolytic Virus Landscape 2017: an analysis of pipeline,stakeholders, deals, industry trends & opportunitiesThe field of oncolytic viruses wasquite dormant in the first decade of the 2000s, characterized ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company

  • $ 912
  • Industry report
  • December 2016

Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates ...

  • Industries : Therapy
  • Countries : United States
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

  • $ 798
  • Industry report
  • November 2016

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics This report describes and evaluates the competitive landscape of CD22-targeted immunotherapeutics based on different treatment ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Oncology
  • Countries : United States
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

  • $ 2793
  • Industry report
  • August 2016

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs The report „TCR & CAR Engineered T-Cell and NK Cell Therapeutics ...

  • Industries : Biopharmaceutical, Biopharmaceutical, Medical Biotechnology
CD123: a paradigmatic target for immunotherapeutic treatment modalities

CD123: a paradigmatic target for immunotherapeutic treatment modalities

  • $ 798
  • Industry report
  • August 2016

CD123: a paradigmatic target for immunotherapeutic treatment modalities This report describes and evaluates the competitive landscape of CD123-targeted immunotherapeutics based on different treatment ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

  • $ 570
  • Industry report
  • June 2016

Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other DiseasesThis Competitive Intelligence report about Bispecific Antibodies for Cancer, Inflammatory & Other Diseases evaluates ...

  • Industries : Biopharmaceutical, Biopharmaceutical, Medical Biotechnology
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update

  • $ 342
  • Industry report
  • May 2016

Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 UpdateTable of Contents1.         2015 Sales of Anti-CD20 Antibodies2.         Originator Anti-CD20 Antibodies ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Therapy
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

  • $ 342
  • Industry report
  • April 2016

Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

  • $ 1083
  • Industry report
  • February 2016

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but „difficult-to-drug“ ...

  • Industries : Medical Biotechnology, Pharmaceutical, Pathology
  • Countries : United States
Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines

  • $ 342
  • Industry report
  • February 2016

Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines The Competitive Intelligence Report „Flavivirus ...

  • Industries : Therapy, Pathology
  • Countries : Japan
Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

  • $ 456
  • Industry report
  • February 2016

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 UpdateThe Competitive Intelligence Report „Anti-VEGF/R Biosimilars and Biosuperiors ...

  • Industries : Oncology, Therapy, Medical Biotechnology
  • Countries : United States
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

  • $ 228
  • Industry report
  • January 2016

The Competitive Intelligence Report Inhibitors of the bromodomain and extra-terminal domain (BET) family as of January 201 provides a competitor analysis in the development pipeline of novel small molecule ...

  • Industries : Cancer
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis

  • $ 2679
  • Industry report
  • November 2015

Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis This report describes and analyzes the situation of antibody-drug conjugates as ...

  • Industries : Medical Biotechnology, Therapy, Pharmaceutical, Biopharmaceutical, Biopharmaceutical
  • Countries : United States
Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines

Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines

  • $ 342
  • Industry report
  • September 2015

Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines The Competitive Intelligence Report Amyloid beta- and Tau-Targeted Antibodies & Vaccines as of September 2015 provides a competito ...

  • Industries : Mental Health
Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson’s Disease

Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson’s Disease

  • $ 237
  • Industry report
  • January 2015

Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease The Competitive Intelligence report about Alpha Synuclein and LRRK2 Inhibitors - Novel Drug ...

  • Industries : Mental Health



ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on